Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Document Type
- Doctoral Thesis (8) (remove)
Language
- English (8) (remove)
Keywords
- ACTH (1)
- Agonist (1)
- Alzheimer Dementia (1)
- Alzheimer-Krankheit (1)
- Amyloid <beta-> (1)
- Antigen (1)
- Astrozytom (1)
- Bildgebung (1)
- Chondrozyten (1)
- Cord blood-derived hematopoietic stem and progenitor cells (1)
Institute
- Medizinische Klinik (bis 2004) (8) (remove)
Background and Aims: PMA is a recently described rare tumor entity occuring most often in young children. Due the worse outcome of PMA-patients as compared to children with pilocytic astrocytoma (PA), it has received a grade II assignment in the latest WHO classification. Nevertheless, increasing evidence suggests that the two tumor types are indeed pathologically and genetically related. The radiological differentiation of PMAs from PAs is challenging and the limited available data could not yet provide unequivocal distinguishing imaging features. Furthermore, it is not completely clarified whether PMA cases are associated with a higher rate of CSF dissemination compared to similarly young patients with PA. The aim of our study was firstly to compare MR/CT imaging features of these tumors, and secondly, to evaluate the occurrence of CSF dissemination.
Material and Methods: The study population included 15 children with PMA and 32 children with PA. A third group consisted of eight children with PAs with focal pilomyxoid features. All cases had been registered in the German multicenter SIOP/HIT-LGG trials. The initial MRIs (and CT scans, if available) at establishing the diagnosis were retrospectively analyzed according to standardized criteria and the findings compared between PMAs and PAs. Furthermore, we compared the occurrence of imaging evidences of CSF tumor dissemination between children with PMA and PA, respectively.
Results: The imaging appearance of PMAs and PAs was very similar. However, PAs tended to show more frequently cystic components (p=0.03). As opposed to PAs, PMAs did not have large tumor cysts. We did not find differences with respect to tumor size and tumor margin. Gadolinium enhancement of PMAs was significantly more frequently homogeneous (p=0.006). PMAs appeared to show more often intratumoral hemorrhages (p=0.047). Furthermore, suprasellar PMAs tended to have a more homogeneus texture on T2-weighted MR images (p=0.026). Within the subgroup < 6 years of age the PMA histology tended to have a larger effect on the occurrence of CSF dissemination than the age (p=0.05 vs.0.12).
Conclusions: Although the radiological appearance of PMAs and PAs is similar, some imaging features, like enhancement pattern or presence of cysts or hemorrhage may help differentiating these low-grade gliomas. Our results corroborate previous scarce data suggesting higher rate of CSF dissemination in PMAs, even in the youngest patient population. Thus, in young children with a chiasmatic-hypothalamic tumor suggestive of a PMA, an intensive search for CSF dissemination along the entire neuraxis should be performed.
Cord blood hematopoietic stem cells (CB-HSCs) are an outstanding source for the treatment of a variety of malignant and non-malignant disorders. However, the low amount of cells collected per donor is often insufficient for treatment of adult patients. In order to make sufficient numbers of CB-HSCs available for adults, expansion is required. Different approaches were described for HSC expansion, however these approaches are impeded by the loss of engrafting potential during ex vivo culture. Little is known about the underlying molecular mechanisms. Epigenetic mechanisms play essential roles in controlling stem cell potential and fate decisions and epigenetic strategies are considered for HSC expansion. Therefore, this study aimed to characterize global and local epigenotypes during the expansion of human CB-CD34+, a well established CB progenitor cell type, to better understand the molecular mechanisms leading to the culture-associated loss of engrafting potential. Human CB-CD34+ cells were cultured using 2 different cytokine cocktails: the STF cocktail containing SCF, TPO, FGF-1 and the STFIA cocktail, which combines STF with Angiopoietin-like 5 (Angptl5) and Insulin-like growth factor-binding protein 2 (IGFBP2). The latter expands CB-HSCs ex vivo. Subsequently, the NOD-scid gamma (NSG) mouse model was used to study the engraftment potential of expanded cells. Engraftment potential achieved by fresh CB-CD34+ cells was maintained when CB-CD34+ cells were expanded under STFIA but not under STF conditions. To explore global chromatin changes in freshly isolated and expanded CB-CD34+ cells, levels of the activating H3K4me3 and the repressive H3K27me3 histone marks were determined by chromatin flow cytometry and Western blot analyses. For analysis of genome-wide chromatin changes following ex vivo expansion, transcriptome profiling by microarray and chromatin immunoprecipitation combined with deep sequencing (ChIP-seq) were performed. Additionally, local chromatin transitions were monitored by ChIP analyses on promoter regions of developmental and self-renewal factors. On a global level, freshly isolated CD34+ and CD34- cells differed in H3K4me3 and H3K27me3 levels. After 7 days of expansion, CD34+ and CD34- cells adopted similar levels of active and repressive marks. Expanding the cells without IGFBP2 and Angptl5 led to a higher global H3K27me3 level. ChIP-seq analyses revealed a cytokine cocktail-dependent redistribution of H3K27me3 profiles. Chemical inhibition of the H3K27 methyltransferase EZH2 counteracted the culture-associated loss of NSG engraftment potential. Collectively, the data presented in this study revealed that by adding epigeneticly active compounds in the culture media we observed changes on a chromatin level which counteracted the loss of engraftment potential. H3K27me3 rather than H3K4me3 may be critical to establish a specific engraftment supporting transcriptional program. Furthermore, I identified a critical function for the Polycomb repressive complex 2-component EZH2 in the loss of engraftment potential during the in vitro expansion of HPSCs. Taken together this thesis provides a better molecular understanding of chromatin changes upon expansion of CB-HSPCs and opens up new perspectives for epigenetic ex vivo expansion strategies.
This thesis concerned the design and examination of a scaffold for tissue engineering applications. The template for the presented scaffold came from nature itself: the intercellular space in tissues that provides structure and support to the cells of the respective tissue, known as extracellular matrix (ECM). Fibres are a predominant characteristic feature of ECM, providing adhesion sites for cell-matrix interactions. In this dissertation a fibrous mesh was generated using the electrospinning technique to mimic the fibrous structure of the ECM. Two base polymers were explored: a biodegradable polyester, poly(D,L-lactide-co-glycolide); and a functional PEG-based star polymer, NCO-sP(EO-stat-PO). This topic was described in three major parts: the first part was materials based, concerning the chemical design and characterisation of the polymer scaffolds; the focus was then shifted to the cellular response to this fibrous scaffold; and finally the in vivo performance of the material was preliminarily assessed. The first steps towards an electrospun mesh started with adjusting the spinning parameters for the generation of homogeneous fibres. As reported in Chapter 3 a suitable setup configuration was on the one hand comprised of a spinning solution that consisted of 28.5 w/v% PLGA RG 504 and 6 w/v% NCO-sP(EO-stat-PO) in 450 µL acetone, 50 µL DMSO and 10 µL of an aqueous trifluoroacetic acid solution. On the other hand an ideal spinning behaviour was achieved at process parameters such as a flow rate of 0.5 mL/h, spinneret to collector distance of 12-16 cm and a voltage of 13 kV. The NCO-sP(EO-stat-PO) containing fibres proved to be highly hydrophilic as the functional additive was present on the fibre surface. Furthermore, the fibres featured a bulk degradation pattern as a consequence of the proportion of PLGA. Besides the morphologic similarity to ECM fibres, the functionality of the electrospun fibres is also decisive for a successful ECM mimicry. In Chapter 4, the passive as well as active functionality of the fibres was investigated. The fibres were required to be protein repellent to prevent an unspecific cell adhesion. This was proven as even 6.5 % sP(EO-stat-PO) in the PLGA fibres reduced any unspecific protein adsorption of bovine serum albumin and foetal calf serum to less than 1 %. However, avidin based proteins attached to the fibres. This adhesion process was avoided by an additional fibre surface treatment with glycidol. The active functionalisation of NCO-sP(EO-stat-PO)/PLGA fibres was investigated with two fluorescent dyes and biocytin. A threefold, chemically orthogonal, fibre modification was achieved with these dyes. The chapters about the chemical and mechanical properties laid the basis for the in vitro chapters where a specific fibre functionalisation with peptides was conducted to analyse the cell adhesion and biochemical expressions. Beginning with fibroblasts in Chapter 5 the focus was on the specific cell adhesion on the electrospun fibres. While NCO-sP(EO-stat-PO)/PLGA fibres without peptides did not allow any adhesion of fibroblasts, a fibre modification with GRGDS (an adhesion mediating peptide sequence) induced the adhesion and spreading of human dermal fibroblasts on the fibrous scaffolds. The control sequence GRGES that has no adhesion mediating qualities did not lead to any cell adhesion as observed on fibres without modifications. While the experiments of Chapter 5 were a proof-of-concept, in Chapter 6 a possible application in cartilage tissue engineering was examined. Therefore, primary human chondrocytes were seeded on fibrous scaffolds with various peptide sequences. Though the chondrocytes exhibited high viability on all scaffolds, an active interaction of cells and fibres was only found for the decorin derived sequence CGKLER. Live-cell-imaging revealed both cell attachment and migration within CGKLER-modified meshes. As chondrocytes undergo a de-differentiation towards a fibroblast-like phenotype, the chondrogenic re-differentiation on these scaffolds was investigated in a long term cell culture experiment of 28 days. Therefore, the glycosaminoglycan production was analysed as well as the mRNA expression of genes coding for collagen I and II, aggrecan and proteoglycan 4. In general only low amounts of the chondrogenic markers were measured, suggesting no chondrogenic differentiation. For conclusive evidence follow-up experiments are required that support or reject the findings. The success of an implant for tissue engineering relies not only on the response of the targeted cell type but also on the immune reaction caused by leukocytes. Hence, Chapter 7 dealt with primary human macrophages and their behaviour and phenotype on two-dimensional (2D) surfaces compared to three-dimensional (3D) fibrous substrates. It was found that the general non-adhesiveness of NCO-sP(EO-stat-PO) surfaces and fibres does not apply to macrophages. The cells aligned along the fibres on surfaces or resided in the pores of the meshes. On flat surfaces without 3D structure the macrophages showed a retarded adhesion kinetic accompanied with a high migratory activity indicating their search for a topographical feature to adhere to. Moreover, a detailed investigation of cell surface markers and chemokine signalling revealed that macrophages on 2D surfaces exhibited surface markers indicating a healing phenotype while the chemokine release suggested a pro-inflammatory phenotype. Interestingly, the opposite situation was found on 3D fibrous substrates with pro-inflammatory surface markers and pro-angiogenic cytokine release. As the immune response largely depends on cellular communication, it was concluded that the NCO-sP(EO-stat-PO)/PLGA fibres induce an adequate immune response with promising prospects to be used in a scaffold for tissue engineering. The final chapter of this thesis reports on a first in vivo study conducted with the presented electrospun fibres. Here, the fibres were combined with a polypropylene mesh for the treatment of diaphragmatic hernias in a rabbit model. Two scaffold series were described that differed in the overall surface morphology: while the fibres of Series A were incorporated into a thick gel of NCO-sP(EO-stat-PO), the scaffolds of Series B featured only a thin hydrogel layer so that the overall fibrous structure could be retained. After four months in vivo the treated defects of the diaphragm were significantly smaller and filled mainly with scar tissue. Thick granulomas occurred on scaffolds of Series A while the implants of Series B did not induce any granuloma formation. As a consequence of the generally positive outcome of this study, the constructs were enhanced with a drug release system in a follow-up project. The incorporated drug was the MMP-inhibitor Ilomastat which is intended to reduce the formation of scar tissue. In conclusion, the simple and straight forward fabrication, the threefold functionalisation possibility and general versatile applicability makes the meshes of NCO-sP(EO-stat-PO)/PLGA fibres a promising candidate to be applied in tissue engineering scaffolds in the future.
The neurodegenerative disorder Alzheimer's disease (AD) is the cause of approximately 60% of the world's 35 million patients suffering from dementia. Current research focuses here are on association with other diseases such as diabetes type 2 (T2DM), possible genetic markers, specific signal transduction pathways within the brain and potential protein modification, because the pathogenesis and etiology of AD are still not fully understood. Specifically association of T2DM with AD came to the focus with the so-called "Rotterdam study" in 1999, indicating that T2DM doubles the risk of developing AD. In the meantime, it is known that the prevalence rate in patients with T2DM is 30%. Drugs commonly used in the treatment of T2DM such as peroxisome proliferator-activated receptors gamma (PPARγ) agonists show improvement of the cognitive abilities in patients with early stage of dementia, with potential therapeutically relevance. Therefore it is important not only to investigate a link between these diseases, but also to investigate the insulin signaling pathway in the brain of AD patients. In order to investigate this complex issue in more details and demonstrate additional links between T2DM and AD, the present study used several basic biological methods to clarify the question: "Is impaired insulin signaling pathway within the brain crucial for the development of AD?" from several points of view. The methods used in this work have been i) an analysis of single nucleotide (SNP) polymorphism of the insulin-degrading enzyme gene (IDE) in relation to risk of AD and / or of T2DM, ii) post-mortem histochemical studies of brain tissue of patients with only AD, with AD combined with T2DM and with only T2DM compared with an age-matched control group, and iii.) investigations of neurochemical pathways and gene/protein expression changes of a human cell culture as a consequences of amyloid β (Aβ) treatment. After analysis of the IDE SNP polymorphism in the selected VITA (Vienna Trans Danube Aging) cohort disease-specific effects were discovered. The upstream polymorphism (IDE2) was found to influence AD risk in a protective manner, while the downstream polymorphism (IDE7) modified the T2DM risk. Based on the SNP results, the presented study delineate the model that IDE promoter and 3‟ untranslated region/downstream variation can have different effects on IDE expression, maybe a relevant endophenotype with disorder-specific effects on AD and T2DM susceptibility. Furthermore, the human post-mortem studies could show that both AD as well as T2DM patients had a significantly lower density of the insulin receptor (IR) in the hippocampus, whereas a significantly increased density of inactive phosphorylated PPARγ has been found and this persisted even in patients with both diseases. Summarizing the histological study, it was possible to reveal common histological features of AD and T2DM, but no direct connection between the two diseases. Although AD is nowadays not only characterized by amyloid-containing plaque deposits and by the hyperphosphorylation of tau protein, the excessive Aβ42 presence in the brains of AD patients is still playing a key role. Up to date it is still not entirely clear which physical form of Aβ42 is responsible for the development of AD. The present work investigated, what impact has the state of aggregation of Aβ42 on genes and proteins of the insulin signaling pathway and the amyloid cascade. It could be shown that the oligomeric variant enhanced specifically the gene and protein expression of glycogen synthase kinase (GSK) 3β and also the enzyme activity was significantly increased, but has in turn strongly inhibited the IR gene and protein expression. Additionally, the effect of Aβ42 on monoamine oxidase B (MAO-B) was examined. An effect of both aggregated forms of Aβ42 had on enzyme activity was discovered. However, the fibrillar variants led to significantly increased activity of MAO-B while the oligomeric variants inhibited the enzyme activity. Several previous studies have demonstrated the involvement of increased MAO-B activity in AD, but the present work provides for the first time a direct link between the states of aggregation of Aβ42 to enzyme activity. Finally the results of the presented thesis can be summarized to following conclusion: Although AD and T2DM sharing some degrees of common features, still there is a lack of direct association, and therefore the diseases must be considered more independent rather than linked. But the impaired cerebral insulin signaling pathway seems to be another manifested hallmark of AD.
A rising percentage of women with risk factors for cardiovascular disease (CVD) reach menopause and experience postmenopausal symptoms. In consequence they require assessment concerning the appropriate combination and safety of a hormone replacement therapy. Clinical trials using the combination of equine estrogens and medroxyprogesterone acetate (MPA) reported an increased risk of thromboembolic events and no cardiovascular protective effects in women receiving this type of hormone replacement therapy. However unopposed estradiol and different regimes estrogens/progestins in vitro and in animal studies have proved to be beneficial for the cardiovascular system. Thus it is possible that the negative outcomes of the clinical trials are an exclusive feature of the regime equine estrogens plus MPA. The present study was initiated to evaluate the cardiovascular effects and possible mechanism of damage of the regime MPA plus 17ß-estradiol in comparison to unopposed 17ß-estradiol during cardiac disease. The role of 17ß-estradiol and MPA during left ventricular dysfunction and chronic heart failure was studied in female Wistar rats that received myocardial infarction. After 8 weeks of treatment the combination of MPA plus estradiol aggravated left ventricular remodelling and dysfunction as judged by increased heart weight, elevated left ventricular end diastolic pressure and decreased left ventricular fractional shortening, effects that were accompanied by increase left ventricular oxidative stress and expression of rac 1 and p67phox regulatory subunits of the NADPH oxidase. In contrast ovariectomy as well as 17ß- estradiol supplementation conferred neutral effects on cardiac function and remodelling post myocardial infarction. Suggesting that the aggravating symptoms of the regime MPA plus 17ß –estradiol are inherent to this pharmacological regime and are not a class effect of the progesterone receptor ligands and are neither due to inhibition of estradiol beneficial effects. Considering that aldosterone plays an important role in the development and aggravation of cardiovascular disease the cardiovascular effects of MPA plus 17ß –estradiol was studied in a model of mineralocorticoid receptor activation and compared to the effects of regimes based in drospirenone, a new progestin with antimineralocorticoid properties. The complex pattern of cardiovascular injury in ovariectomized Wistar rats induced by 8 weeks of continuous chronic aldosterone infusion and high-salt diet was significantly attenuated in sham-ovariectomized rats and by coadministration of 17 ß-estradiol in ovariectomized animals. The beneficial role of 17 ß-estradiol on blood pressure, cardiac hypertrophy, vascular osteopontin expression and perivascular fibrosis was completely abrogated by coadministration of MPA. In contrast, drospirenone was either neutral or additive to 17 ß-estradiol in protecting against aldosterone salt-induced cardiovascular injury and inflammation. Taking into account that the kidney plays a major role for the development and aggravation of hypertension a further characterization of fluid balance, renal morphology and renal gene expression in the aldosterone salt treated rats was conducted. Aldo-salt treatment resulted in remnant kidney hypertrophy without structural damage, effects that were not modified by 17 ß-estradiol. However combination of MPA with 17 ß-estradiol enhanced kidney hypertrophy, fluid turnover, renal sodium retention and potassium excretion and was associated with increased renal ENaC expression, extensive renal lesions, tubular damage and enhanced p67phox expression and protein tyrosin nitrosylation. Different to the protective effects of drospirenone that included a complete blockade of kidney hypertrophy and sodium retention and enhanced renal expression of angiotensin II type-2 receptors. Therefore the loss of 17 ß-estradiol cardiovascular beneficial effects and the renal harmful effects in the aldosterone salt treated rats receiving MPA can not be extrapolated to other progestins. Indeed drospirenone conferred protective effects due to its antimineralocorticoid properties. In conclusion, the choice of specific synthetic progestins has profound implications on the development of cardiovascular and renal injury; MPA aggravated cardiac disease, which contributes to explain the adverse outcomes of clinical trials on the prevention of cardiovascular disease by combined estrogen and MPA treatment.
Cardiovascular disease is the major cause of mortality morbidity in both men and women in industrialized countries. The incidence of cardiovascular diseases in pre-menopausal women is lower compared to age-matched men but the risk of heart diseases increases dramatically after the onset of menopause.Therefore, it has been postulated that female sex hormones play an important role in cardiovascular health in pre-menopausal women. In contrast to clinical data, which failed to show positive estrogen effects on cardiovascular system of post- menopausal women, extensive experimental studies indicated cardioprotective effects of estrogens in laboratory animals. The majority of experimental estrogen substitution studies were performed with young individuals, thus the effects of ageing remain neglected and are poorly understood. The present project is the first attempt to study the cardiac effects of each estrogen receptor isoform (estrogen receptor alpha (ERa) and estrogen receptor beta (ERb)) in adult (“menopausal”) and senescent (“post- menopausal”) hypertensive rats. The female senescent spontaneously hypertensive rats (SHR) served as a model system for age- associated hypertension in females whereas young individuals were used for control experiments. Young and senescent SHR rats were treated with 17b- estradiol as well as new estrogen receptor isoform selective ligands 16a-LE2 (ERa agonist) and 8b-VE2 (ERb agonist). The results showed different functions of both estrogen receptor isoforms in cardiovascular system: ERa attenuated cardiac hypertrophy but not hypertension whereas ERb could significantly reduce both, blood pressure and cardiac hypertrophy. Surprisingly, both agonists and 17b- estradiol were effective in young animals but not in senescent SHR rats. These findings match with the clinical data and could be related to altered estrogen metabolism in senescent rats, since estrogen plasma levels did not increase to measurable extent in senescent animals receiving estrogen. Estrogen is metabolized by several 17b- hydroxysteroid dehydrogenase isoforms. In the current study, 17b- hydroxysteroid dehydrogenase type 10 (17b- HSD10) was identified as a novel protein- protein interaction partner of estrogen receptor alpha ligand binding domain (ERaLBD) in human heart. Cellular localization experiments of ERa in the cardiac myocytes showed nuclear and cytosolic localization pattern which overlapped partially with that of cardiac mitochondria. 17b-HSD10 is localized only in mitochondria. Direct interaction of both proteins was confirmed by pull- down experiments where 17b-HSD10 could be co-precipitated with ERa. Interestingly, protein interaction could be detected only under estrogen- free conditions whereas the presence of estrogen in the system blocked this interaction. Enzymatic assay which was developed in our laboratory, helped to define functional relevance of this interaction. The data obtained from enzymatic assays and protein- protein interaction studies strongly suggest that estrogen receptor could play an important role in the control of intracellular (or mitochondrial) estogen metabolism. The second potential ERa interaction partner in the heart- bladder cancer associated protein 10 (BLCAP10) - was initially identified in non- invasive bladder cancer cell lines. BLCAP10 protein expression in the heart as well as its localization pattern in cardiac myocytes is shown in the last part of the theses. Due to perinuclear localization similarity with ERb, we conclude that BLCAP10 could interact with ERb rather than with ERa. Poor BLCAP10 protein overexpression and toxicity in both, bacteria and eukaryotic cells, suggested that BLCAP10 could be involved in cell- cycle and/ or protein expression control. In summary, the results showed that isoform selective activation of estrogen receptors exert divergent effects in the cardiovascular system both by upregulation of aMHC expression or by lowering blood pressure. Hormones were effective in young animals but had only minor effects in senescent rats. The new ERa protein- protein interaction partners identified during the project provide new information about estrogen receptor function in the heart and its possible role in the regulation of estrogen homeostasis.
Integrins are transmembrane receptors transmitting mechanical signals from the extracellular matrix (ECM) to the cytoskeleton (outside-in-signaling). Many molecular defects in the link between cytoskeleton and ECM are known to induce cardiomyopathies. alpha v integrin appears to play a major role in several processes relevant to remodeling, such as binding and activation of matrix metalloproteinases as well as regulation of cell proliferation, migration, and differentiation. We hypothesized that alpha v integrin-mediated signaling is required for the compensatory hypertrophy after aortic banding (AB) and associated with the modulation of ECM protein expression. Mice were treated in vivo with a specific integrin alpha v inhibitor or vehicle via osmotic minipumps starting 1 day prior to aortic banding (AB). At day 2 and day 7 following AB or sham-operation, the mice were examined by echocardiography and hemodynamic analyses were performed. Treatment of alpha v Integrin inhibitor led to a dilated cardiomyopathy and congestive heart failure in AB mice (dilated left ventricle, depressed LV function, and pulmonary congestion), but not to hypertrophy as observed in mice without inhibitor treatment. Investigation of downstream signaling revealed significant activation of the p38 Mitogen-Activated Protein Kinase (MAPK), the Extracellular signal-Regulated Kinases 1 and 2 (Erk 1/2), Focal Adhesion Kinase (FAK) and tyrosine-phosphorylation of c-Src in mice 7 days after AB. This response was blunted in mice treated with integrin alpha v inhibitor. Microarrays probing for a total of 96 cell adhesion and ECM genes identified various genomic targets of integrin alpha v mediated signalling. 7 days after AB 18 ECM genes were up-regulated more than 2-fold (n=6), e.g. collagen (8.11 ± 2.2), fibronectin (2.32 ± 0.94), secreted protein, acidic and rich in cysteine (SPARC, 3.78 ± 0.12), A disintegrin-like and metalloprotease (reprolysin type) with trombospondin type 1 (Adamts-1, 3.51 ± 0.81) and Tissue inhibitor of metalloproteinase 2 (TIMP2, 2.23 ± 0.98), whereas this up-regulation was abolished in mice that were treatd by integrin alpha v inhibitor via mini pumps. We conclude that signaling downstream of integrin alpha v is mediated by the MAPK, FAK and c-Src pathways leading to an up-regulation of extracelluar matrix components necessary for the compensatory response of the heart under a condition of pressure overload.
In mammals, the pituitary-derived neuropeptide adrenocorticotropic hormone (ACTH) is a major regulator of adrenocortical steroidogenesis and hormone secretion. However, the mechanism by which adrenal growth is governed by pituitary signals and the role of the pituitary in early adrenal development remain to be investigated. In this work the model organism zebrafish was used to elucidate pituitary adrenal interactions during early vertebrate development. The adrenal homologue in zebrafish is located in the head kidney and termed interrenal organ. The work deals with the analysis of pituitary-interrenal interactions by using pituitary mutants, gene-knockdown embryos and pharmacological interventions. As prerequisite to the main study, zebrafish pomc gene was cloned and characterized and the interrenal organogenesis in wild-type zebrafish was analysed.